Lloyd Advisory Services’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Lloyd Advisory Services’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-468	Closed	-$49K	–	608
2022 Q1	$49K	Buy	468 +2	+0.4%	+$195	0.02%	232
2021 Q4	$50K	Hold	466	–	–	0.02%	205
2021 Q3	$51K	Sell	466 -35	-7%	-$3.63K	0.03%	159
2021 Q2	$47K	Hold	501	–	–	0.02%	161
2021 Q1	$46K	Buy	+501	New	+$42.3K	0.03%	142

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Lloyd Advisory Services's HZNP Position: Q2 2022 in Review

Lloyd Advisory Services sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 468 shares — an estimated $49K sold.

Lloyd Advisory Services first reported a position in HZNP in Q1 2021 and held it in 5 quarters. The position peaked at $51K in Q3 2021. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

Lloyd Advisory Services reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Lloyd Advisory Services sold 468 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $49K.
Lloyd Advisory Services first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 5 quarters.
Lloyd Advisory Services's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $51K in Q3 2021.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Lloyd Advisory Services's 13F filing for Q2 2022, filed 15 Aug 2022.